HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IPHA
Innate Pharma S.A.
There isn't enough reported data to score IPHA yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IPHA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
IPHA's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IPHA PE Valuation
IPHA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IPHA Forward outlook
There aren't enough analyst estimates for IPHA to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over IPHA in the latest year-over-year earnings comparison.
IPHA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$0.61 | +$0.07 |
| Q2 2025 | -$0.61 | -$0.14 |
| Q4 2024 | -$0.68 | -$0.58 |
| Q2 2024 | -$0.47 | +$0.41 |
| Q4 2023 | -$0.10 | +$0.71 |
| Q2 2023 | -$0.88 | -$0.57 |
| Q4 2022 | -$0.81 | -$0.08 |
IPHA is still losing money, but less than at its worst: $0.61 per share over the past year, against $0.88 at its worst in mid-2023.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over IPHA in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over IPHA on profitability, with a higher operating margin.
IPHA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3.5M | -35% |
| Q4 2025 | $4.6M | -47% |
| Q2 2025 | $5.4M | -61% |
| Q4 2024 | $8.6M | -64% |
| Q2 2024 | $13.7M | -69% |
| Q4 2023 | $23.8M | +77% |
| Q2 2023 | $44.7M | -12% |
| Q4 2022 | $13.4M | +34% |
IPHA's revenue has slid since its 2018 peak: $4M last quarter, down 74% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -692% | -479 points |
| Q4 2025 | -690% | -632 points |
| Q2 2025 | -523% | -522 points |
| Q4 2024 | -325% | +221 points |
| Q2 2024 | -213% | -232 points |
| Q4 2023 | -57% | +191 points |
| Q2 2023 | -1% | +161 points |
| Q4 2022 | -545% | -481 points |
IPHA's operating margin was −692% last quarter, down 479 points from the same quarter a year ago, near the bottom of its range since 2012.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
IPHA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$23.8M | +$10.9M |
| Q4 2025 | -$24.1M | -$12.9M |
| Q2 2025 | -$34.7M | -1234% |
| Q4 2024 | -$11.2M | +$12.3M |
| Q2 2024 | $3.1M | +$16.1M |
| Q4 2023 | -$23.5M | -$719.9K |
| Q2 2023 | -$13.1M | -1575% |
| Q4 2022 | -$22.8M | +$8.3M |
IPHA has burned cash in most quarters: −$94M over the past year, against −$56M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IPHA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IPHA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.7% | +4.2M shares |
| 1 year | +16% | +13M shares |
| 3 years | +19% | +14.9M shares |
| 5 years | +74% | +40M shares |
| Available history | +147% | +55.9M shares |
IPHA has 94M diluted shares, up 16% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2020 | — |
| Q2 2020 | — |
| Q4 2019 | — |
| Q2 2019 | — |
| Q4 2018 | — |
| Q2 2018 | — |
| Q4 2017 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IPHA Net Leverage
IPHA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IPHA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.8 | Neutral |
| Stochastic | 8.2 | Oversold |
IPHA's weekly RSI is 42 (neutral) and its Stochastic is 8 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IPHA PE vs Healthcare Sector
IPHA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IPHA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.53 | 2.6% below |
| 20 week MA | $1.77 | 16% below |
| 50 week MA | $1.71 | 13% below |
| 100 week MA | $1.85 | 19% below |
| 200 week MA | $2.23 | 33% below |
IPHA is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IPHA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.50 | $4.27 | -34% |
| 2021 | $4.27 | $5.17 | +21% |
| 2022 | $5.17 | $2.81 | -46% |
| 2023 | $2.81 | $2.80 | -0.4% |
| 2024 | $2.80 | $2.11 | -25% |
| 2025 | $2.11 | $1.75 | -17% |
| 2026 YTD | $1.75 | $1.49 | -15% |
IPHA has the edge over HIMS on returns for 2026, with the stronger performance.